172 related articles for article (PubMed ID: 15308010)
21. Nilotinib significantly induces apoptosis in imatinib-resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts.
Ekiz HA; Can G; Gunduz U; Baran Y
Hematology; 2010 Feb; 15(1):33-8. PubMed ID: 20132660
[TBL] [Abstract][Full Text] [Related]
22. [K562 cell line resistance to nilotinib induced in vitro and preliminary investigation of its mechanisms].
Wang JS; Yang C; Fang Q; Wei SX; Chen C; Yang Y; Wang YT; Hu XY; Ma D
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):906-10. PubMed ID: 23363745
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro.
Ferrao PT; Frost MJ; Siah SP; Ashman LK
Blood; 2003 Dec; 102(13):4499-503. PubMed ID: 12881321
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway.
Kurosu T; Wu N; Oshikawa G; Kagechika H; Miura O
Apoptosis; 2010 May; 15(5):608-20. PubMed ID: 20094798
[TBL] [Abstract][Full Text] [Related]
25. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
[TBL] [Abstract][Full Text] [Related]
27. [Effect of A Novel Emodin Derivative on Chronic Myelogenous Leukemia K562 Cells and Imatinib-resistant K562/G01 Cells].
Li BJ; Liu TB; Wang WF; Lin MH; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):1-7. PubMed ID: 26913384
[TBL] [Abstract][Full Text] [Related]
28. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
[TBL] [Abstract][Full Text] [Related]
29. Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.
Kurzrock R; Talpaz M; Li L; Estrov Z
Leuk Lymphoma; 2006 Aug; 47(8):1651-64. PubMed ID: 16966279
[TBL] [Abstract][Full Text] [Related]
30. Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro.
Liu H; Li H; Feng Z; Tai J; Meng Y; Wang H; Xin H; Zhang S; Zuo M; Zhang Y; Chen X
Leuk Lymphoma; 2009 Mar; 50(3):437-46. PubMed ID: 19347730
[TBL] [Abstract][Full Text] [Related]
31. Guggulsterone of Commiphora mukul resin reverses drug resistance in imatinib-resistant leukemic cells by inhibiting cyclooxygenase-2 and P-glycoprotein.
Xu HB; Xu LZ; Mao XP; Fu J
Phytomedicine; 2014 Jun; 21(7):1004-9. PubMed ID: 24680616
[TBL] [Abstract][Full Text] [Related]
32. Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin.
Demidenko ZN; An WG; Lee JT; Romanova LY; McCubrey JA; Blagosklonny MV
Cancer Biol Ther; 2005 Apr; 4(4):484-90. PubMed ID: 15846067
[TBL] [Abstract][Full Text] [Related]
33. Imatinib inhibits the expression of SCO2 and FRATAXIN genes that encode mitochondrial proteins in human Bcr-Abl⁺ leukemia cells.
Papadopoulou LC; Kyriazou AV; Bonovolias ID; Tsiftsoglou AS
Blood Cells Mol Dis; 2014; 53(1-2):84-90. PubMed ID: 24726617
[TBL] [Abstract][Full Text] [Related]
34. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
[TBL] [Abstract][Full Text] [Related]
36. Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.
Kirschner KM; Baltensperger K
Mol Cancer Res; 2003 Nov; 1(13):970-80. PubMed ID: 14638869
[TBL] [Abstract][Full Text] [Related]
37. Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib.
Mor-Tzuntz R; Uziel O; Shpilberg O; Lahav J; Raanani P; Bakhanashvili M; Rabizadeh E; Zimra Y; Lahav M; Granot G
Exp Hematol; 2010 Jan; 38(1):27-37. PubMed ID: 19837126
[TBL] [Abstract][Full Text] [Related]
38. Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.
Monteghirfo S; Tosetti F; Ambrosini C; Stigliani S; Pozzi S; Frassoni F; Fassina G; Soverini S; Albini A; Ferrari N
Mol Cancer Ther; 2008 Sep; 7(9):2692-702. PubMed ID: 18790751
[TBL] [Abstract][Full Text] [Related]
39. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments.
Xu L; Zhao Y; Pan F; Zhu M; Yao L; Liu Y; Feng J; Xiong J; Chen X; Ren F; Tan Y; Wang H
Biomed Res Int; 2019; 2019():6502793. PubMed ID: 31828114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]